病毒发病机制的 ART 调节-猫眼课题宝

病毒发病机制的 ART 调节

批准号：

10609801

负责人：

Dirk P Dittmer

金额：

$36.93万

依托单位：

UNIV OF NORTH CAROLINA CHAPEL HILL

依托单位国家：

美国

项目类别：

财政年份：

2007

资助国家：

美国

项目状态：

未结题

起止时间：

2007-05-15 至 2025-04-30

来源：

https://reporter.nih.gov/project-details/10609801

关键词：

AIDS clinical trial group Acquired Immunodeficiency Syndrome Affect Basic Science Biological Assay Biology CD4 Lymphocyte Count Cells Cercopithecine Herpesvirus 1 Clinical DNA Disease Endothelial Cells Epigenetic Process Funding Genetic Transcription Goals HIV HIV Seronegativity HIV Seropositivity HIV/AIDS Human Human Herpesvirus 4 Human Herpesvirus 8 Immune Immunosuppression Interruption Kaposi Sarcoma Lesion Long-Term Effects Malignant Neoplasms Messenger RNA MicroRNAs Mission Molecular Mouth Diseases National Institute of Dental and Craniofacial Research Nelfinavir Oral Oral cavity Outcome Palate Kaposi&apos s Sarcoma Patients Persons Pharmaceutical Preparations Protease Inhibitor Public Health Publications Regimen Reporting Research Resources Risk Role Route Saliva Sampling Severity of illness Shock Stratification Vertical Disease Transmission Viral Viral Load result Viral Pathogenesis Virus antiretroviral therapy clinical application clinical investigation co-infection comorbidity epigenome exosome extracellular vesicles improved low and middle-income countries oral HIV patient safety programs response transmission process

项目摘要

项目成果

Dirk P Dittmer的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要在美国，大多数人免疫缺陷病毒1型感染患者都是长期（10年以上）联合抗逆转录病毒治疗（cART）。虽然cART将HIV复制抑制到50拷贝/ml以下，但关于cART对卡波西肉瘤相关疱疹病毒（KSHV）的长期作用，传播，口腔和全身KS疾病或潜在的KSHV水库。我们建议调查不同的cART成分对KSHV和KS疾病的影响，长期目的是中断口服KSHV 防止艾滋病毒/艾滋病感染者传播和治愈病毒。具体而言，我们将侧重于调整 KSHV的再活化以及cART药物如何影响KSHV外泌体/细胞外囊泡。这是一个竞争 PA-16-426/“高”或“中”优先艾滋病研究（非艾滋病定义）或艾滋病定义的癌症（R 01）。

英文摘要

Project Summary Abstract The majority of human immune deficiency virus 1 infected patients in the US are on long-term (10+ years) combination antiretroviral therapy (cART). While cART suppresses HIV replication to below 50 copies/ml, not much is known about the long-term effect of cART on Kaposi sarcoma associated herpesvirus (KSHV) oral transmission, oral and systemic KS disease or the latent KSHV reservoir. We propose to investigate the impact that different cART components have on KSHV and KS disease with the long-term aim to interrupt oral KSHV transmission and cure the virus from persons living with HIV/AIDS. Specifically, we will focus on modulating the reactivation of KSHV and how cART drugs affect KSHV exosomes/ extracellular vesicles. This is a competitive renewal application in response to PA-16-426/ "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01).

期刊论文(18)

专著(0)

科研奖励(0)

会议论文